© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
May 07, 2018
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
December 13, 2017
Transformative therapies with high up-front costs will exacerbate the need to address gaps between payers when costs and benefits occur at different times.